Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind trial of subcutaneous amlitelimab in moderate-to-severe atopic dermatitis
jRCT2061230090Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of amlitelimab in atopic dermatitis (AD) (3 arms), sponsored by Sanofi. Primary endpoints: Proportion of participants with vIGA-AD 0 or 1 and ≥2-point reduction at Week 24 (EU, EU reference countries, Japan), Proportion of participants reaching EASI-75 at Week 24 (EU, EU reference countries, Japan) and 1 more. Started Jan 2024; status: completed.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2061230090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230090.